WilmerHale Represents Thermo Fisher Scientific in Transaction with GE Healthcare

WilmerHale Represents Thermo Fisher Scientific in Transaction with GE Healthcare

Firm News

WilmerHale represented Thermo Fisher Scientific in a transaction with GE Healthcare announced today. Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for approximately $1.06 billion. The businesses will become part of GE Healthcare's Life Sciences division.

WilmerHale Partner Hal Leibowitz led the team advising Thermo Fisher. Other members on the WilmerHale team included partners from the corporate, tax, benefits, real estate and IP practices: Jeffrey Hermanson, Joseph Conahan, Rob BurkeAmy Null, Keith Barnett, Paul Jakubowski and Steve Barrett.

A press release discussing the transaction in greater detail is available on Thermo Fisher's website.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.